Abstract. Ruthenium complexes [1] [2] [3] with oxalato, amido and pyridine ligands have been synthesized and characterized. Biological tests showed that the ruthenium complexes 2 and 3 have modest cytotoxicity on both murine cell line NIH3T3 and human cancer colon cell lines HCT116 and HT29 while complex 1 has no obvious growth defect. We further tested why complexes 2 and 3 exhibit modest cytotoxicity. Gel electrophoresis analysis demonstrates that complex 3 has the ability to cleave double-stranded DNAs in a dose-dependent manner. In contrast, complex 2 does not have detectable DNA cleavage activity. Additionally, real-time PCR analysis suggests that the observed cell growth inhibition or death could be due to the altered gene expression in the processes of cell cycle and apoptosis/necrosis caused by the addition of complexes 2 and 3. Furthermore, cell death by DNA fragmentation assay indicates that the addition of these two complexes may cause cell necrosis rather than apoptosis.
Introduction
The discovery of antitumor activity of cisplatin and other platinum derivatives has been evaluated by both in vitro cellbased assays and in vivo animal models (1) (2) (3) (4) (5) (6) (7) (8) . Following the discovery of cisplatin and cisplatin derivatives, there have been tremendous efforts aimed at investigating anticancer activity of metal-based complexes to reduce toxic sideeffects and increase drug specificity and activity. Over the years, much attention has been focused on developing cisplatin analogues. Currently, cisplatin, carboplatin and oxaplatin are widely used anticancer drugs, and are especially effective against testicular and ovarian carcinomas, bladder tumors and tumors of the head and neck (9) . It is generally believed that the ultimate target of this type of drug is DNA (10) . The DNA adducts formed interfere with DNA transcription and replication, eventually leading to cell death (11) . Cisplatin is relatively unreactive in high-chloride media (e.g., blood plasma) and is activated by hydrolysis of near DNA in the nucleus. In contrast, carboplatin and oxaplatin are relatively inert to hydrolysis, have a milder spectrum of side-effects and probably attack DNA by means of chelate ring-opening reactions (12) . Platinum-derived drugs have massive impact on current cancer therapy, however, patients suffer from a wide range of side-effects (13) . Additionally, platinumderived drugs are often limited to the types of cancer that are treated due to drug resistance (14, 15) .
To achieve anticancer activity in a broader range of tumors and/or overcome the problems associated with platinumderived drugs, novel non-platinum and in particular ruthenium complexes with potential antitumor activity are being developed (15, 16) . Ruthenium organometallic complexes have a spectrum of activity, suggesting that they might not share cross-resistance mechanisms with cisplatin although the primary cytotoxic lesion remains to be identified (17) (18) (19) (20) (21) . Clearly, ruthenium complexes represent a new class of compounds endowed with antitumor activity (1, 22) . Two ruthenium complexes NAMI-A and KP1019 are already in clinical trials (23) (24) (25) (26) (27) . Ruthenium complexes are rich in chemistry and the side-effects of the ruthenium complexes are low compared to platinum-derived drugs because of the selective activation to cytotoxic species in solid tumor tissues (28) . Ruthenium complexes display relatively low ligand exchange rates in comparison to platinum complexes (29) . Slow ligand exchanges ensure that a drug reaches its biological target without prior modification. In addition, the various oxidation states (II, III and IV) of ruthenium are all accessible under physiological conditions (29) . In these complexes, the ruthenium center is primarily hexacoordinated with octahedral geometry in contrast to square planar geometry of platinum (II) (30) . The octahedral geometry of ruthenium complexes imposes not only different steric effects upon interaction with biomolecules, which in turn may cause a different anticancer profile from cisplatin, but also various other different properties (31) .
We report herein synthesis and characterization of the ruthenium complexes with ligands of oxalato, amido and pyridine. We found that two ruthenium complexes with either amido or pyridine ligand showed modest anticancer activity. 3 (H 2 bpb], the ruthenium complex 2. Cyclic voltametry was carried out with a three electrode system comprised of a Pt counter electrode, a Pt disk working electrode, and a saturated calomel electrode (SCE) connected to the main cell compartment by a KCl salt bridge. Potential control was done with a BAS CV-50 W voltametric analyzer used in the cyclic voltametry mode. The supporting electrolyte was 0.100 M tetrabutylammonium hexafluorophosphate. Argon was bubbled through the solution for at least 30 min prior to and during cyclic voltametry. Instrumental IR compensation was used when needed. 3 (DMSO) 2 (py)], the ruthenium complex 3, was prepared and characterized by literature procedures (32) .
Materials and methods

Synthesis of K[RuCl(TMSO)
Synthesis and characterization of the ruthenium complex 3. mer-[RuCl
Plasmid DNA isolation and gel electrophoresis. pUC19 plasmid was introduced into DH5· competent cells based on manufacturer's protocol (Invitrogen Corporation, Carlsbad, CA). A single colony was selected from LB plate and cultured in 5.0 ml of LB medium at 37˚C in a shaker at a speed of 300 rpm for overnight. This starter cell culture was diluted 1:500 using freshly prepared LB medium and grew at 37˚C in a shaker at a speed of 300 rpm for 16-18 h. Cells were harvested at 4,000 rpm for 5 min. The plasmid DNAs were purified from the cell culture using a Qiagen plasmid purification column based on manufacturer's protocol (Qiagen Inc., Valencia, CA). LB medium and plates contained 100 μg/ml ampicillin. The concentration of plasmid DNA was determined by the absorbance at 260 nm using UV-Vis spectrophotometry. Approximately 1.0 μg of pUC19 plasmid DNA was incubated with the ruthenium complexes 1, 2 and 3 at the specified concentrations in a total 20 μl in a 37˚C water bath for 2-32 h (33) . At the end of incubation, bromophenol blue loading buffer was added. The samples were then loaded on a 1.0% agarose gel containing ~2.0 μg/ml ethidium bromide. Gel electrophoresis was carried out at 150 V for ~20 min in Tris-Borate-EDTA (TBE) buffer. Bands were visualized by UV light and photographed by a Bio-Rad gel documentation system (Bio-Rad Laboratories, Hercules, CA).
Culture of cell lines and cytotoxicity test.
The human and murine cell lines were maintained in either T25 or T75 flasks containing DMEM medium supplemented with 10% fetal bovine serum, 1% glutamine, and 1% penicillin and streptomycin (Invitrogen) in the standard 3T3 protocol and grown at 37˚C in a 5% CO 2 incubator (34). The ruthenium complexes dissolved in DMSO, filter-sterilized, were added into a growth medium using 1:1000 dilution to avoid the toxic effects of DMSO after the cells were plated for 24 h. At the end of incubation with ruthenium complexes, cells were removed from flasks by trypsin-EDTA solution (Invitrogen). Cell viability was determined by the trypan blue staining and cell number was counted using a haemocytometer.
Total RNA extraction and qRT-PCR. Total RNA was isolated from the cell lines using TRIzol reagents (Invitrogen). cDNA was generated from 500 ng total RNAs using superscript II reverse transcriptase (Invitrogen). qRT-PCR was performed on a MyiQ real-time PCR machine (Bio-Rad) using Qiagen SYBR-Green PCR master mix (Qiagen). qPCR primers were designed using Primer Express software (Applied Biosystems, Foster City, CA) and only sense primer and antisense primer from different exons were chosen for qRT-PCR analysis except the genes containing only one exon. A single product for each primer pair was further confirmed by gel and melt-curve analysis. mRNA level for each gene was normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
Total genomic DNA isolation. The genomic DNA was isolated by modified earlier protocol (35) . Cells were harvested by centrifugation at 4,000 rpm for 5 min and washed with PBS once. The cell pellets were then re-suspended in 500 μl of lysis buffer [2.0 mM EDTA/100 mM Tris-Cl, pH 8.0/0.8% (w/v) SDS] and 50 μl of 10 mg/ml proteinase K was added. The lysate was mixed well and incubated at 37˚C overnight. Phenol-chloroform (300 μl) (pH 7.5) was added to the lysate and vortexed for 30 sec twice. After centrifugation at 13,000 rpm for 10 min, the aqueous phase was transferred into a new 1.7 ml micro-centrifuge tube. Genomic DNA was precipitated by 1.0 ml of isopropanol and washed once using 70% ethanol. DNA was dissolved to 10.0 mM. Tris buffer, pH 7.5 and 10.0 μl of 10 mg/ml RNase A was added. The samples were incubated in a 37˚C water bath for 2 h to remove RNA. Extracted genomic DNA solutions were applied to a 1.0% agarose gel, electrophoresed and stained by ethidium bromide.
Statistical analysis. Experimental data were subjected to computer-assisted statistical analysis of variance (ANOVA), Student's t-test and Dunnett's post test using GraphPad Prism 4.0 (GraphPad Software Inc., La Jolla, CA). Differences of p<0.05 were considered to be significantly different from controls.
Results
The synthesis of the ruthenium complexes 1 and 2, and the X-ray structure of the ruthenium complex 2. A mononuclear K[RuCl(TMSO) 3 3 ] with H 2 bpb in refluxing dichloromethane. This complex has a distorted octahedral geometry around a ruthenium center.
The X-ray molecular structure of 2 is shown in Fig. 1 . The selected bond angles and distances are listed in Table I . The tetradentate ligand H 2 bpb in its deprotonated form provides two neutral pyridine nitrogen and two anionic carboxamido nitrogen donors in the equatorial plane while the axial plane is occupied by two chlorides. The geometry around ruthenium is distorted octahedral. The average Ru-N amide distance 1.9419 Å is considerably shorter than the average Ru-N py distance 2.0864 Å. The average Ru-Cl bond length 2.355 Å is comparable to the Ru-Cl distance reported for tetradentate (N 2 O 2 ) ligands such as H 2 -salen, substituted H 2 -salophen and H 2 bpb derivatives (Table II) .
Electrochemical study of the ruthenium complex 2. Cyclic voltammetry of trans-[RuCl 2 (H 2 bpb], the ruthenium complex 2, was carried out at sweep rates ranging between 100 to 3011 mV/s. Fig. 2 shows the last two of five sweeps carried out at 1003 mV/s. Higher sweep rates gave similar graphs. Lower sweep rates displayed signals at cathodic potentials due to further reduction and subsequent oxidation, possibly of separate ligands. The peaks in Fig. 2 are likely due to the Ru(III)/Ru(II) redox couple. The peak separation of 167 mV indicates an irreversible process.
Effects on cell viability by the ruthenium complexes 1, 2 and 3.
A number of ruthenium complexes were reported to have anti-metastatic activity (37) (38) (39) . Specifically, a certain ruthenium complexes with heterocycles coordinated to ruthenium center through nitrogen have been shown to act as cytostatic and cytotoxic drugs on colorectal tumor cells both Table I . The crystal data for the ruthenium complex 2. (40) (41) (42) (43) . In the present work, the effects of the ruthenium complexes 1, 2 and 3 with ligands of oxalato, amido and pyridine on cell growth were investigated using two human colorectal carcinoma cell lines (HCT116 and HT29). Additionally, we also investigated the cytotoxicity of these complexes using a cell model constituted by a culture derived from NIH3T3 mouse fibroblast line (NIH3T3) obtained after prolonged serum deprivation (4). Fig. 3 reports the effects of 1, 2 and 3 on in vitro cultured NIH3T3 cells treated for three days at concentrations of 0, 50, or 250 μg/ml. Our data suggest that 2 (250 μg/ml = 434 μM) and 3 (250 μg/ml = 565 μM) can inhibit NIH3T3 while 1 has no obvious cell growth defect. Our experimental results of 1, 2 and 3 on in vitro cultured HCT116 and HT29 cells indicate that complexes 2 and 3 can inhibit the growth of two colon cancer cell lines in a dose-dependent fashion. Similar to NIH3T3 cells, complex 1 has no anticancer activity. In summary, a detectable reduced cell number was observed in NIH3T3, HCT116 (Fig. 4a-c) , and HT29 (data not shown) cells caused by the addition of 2 and 3. When the cells were grown with 2 and 3 for a longer period of time, all the cells died while the control cells were still alive. This was confirmed by trypan blue staining.
-------------------------------------------------
------------------------------------------------in vivo and in vitro
DNA binding activity by the ruthenium complexes 2 and 3.
Ruthenium complexes have been reported to have DNA binding properties (44) (45) (46) (47) (48) . The observed cell growth inhibition of complexes 2 and 3 made us hypothesize that 2 and 3 might have the property of either DNA binding, or cross-linking, or cleavage. Agarose gel electrophoresis was used to identify the possible interactions of 2 and 3 with plasmid DNA. A plasmid pUC19 with 2,686 base-pairs in length and with a high copy number was chosen in this study. pUC19 is a commonly used plasmid cloning vector, which carries a 54 base-pair multiple cloning site polylinker that contains unique sites for 13 different hexanucleotide-specific restriction endonucleases. It can be easily linearized by any of these restriction endonucleases. Plasmid DNA naturally exists as a supercoiled molecule, which is often called form I. The majority of purified plasmid DNA in a laboratory is a covalently closed supercoiled molecule. If one or more phosphate bonds anywhere in the backbone of supercoiled DNA are broken, the molecule unravels to a relaxed open circular DNA (form II). The linear plasmid DNA, which is called form III, can be generated if the phosphodiester bonds of both strands are broken at the same place. Different forms of the same plasmid can be identified by agarose gel electrophoresis since they will migrate at different positions in the agarose gel. If complexes 2 and 3 can interact with the double-stranded DNA, we expect to identify the altered migration patterns of any forms in agarose gel. Gel electrophoresis clearly demonstrated that complex 3 can interact with plasmid DNA in a dose-dependent manner since form I was converted to form II (Fig. 5) . In contrast, complex 2 does not have DNA binding properties (data not shown). It has been demonstrated that ruthenium complexes can crosslink to the linear DNA since linear DNA has phosphate and hydroxyl ends. In order to test this possibility, pUC19 DNA was linearized by EcoRI and incubated with complexes 2 and 3. The results show there are no obvious altered migration patterns. Complex 1 does not have a DNA binding property (data not show).
Gene expression of the ruthenium complexes 2 and 3 in NIH3T3.
Our experimental data suggest that complexes 2 and 3 can inhibit the growth of HCT116, HT-29 and NIH 3T3. We further investigated the molecular mechanism of this cell growth inhibited by these two complexes by testing gene expression in the process of cell death and cycle using realtime RT-qPCR, which measures mRNA from NIH3T3 cells following 18-h treatment with 174 μM complex 2 and 226 μM 3. Test gene expression was normalized to GAPDH mRNA. Tumor suppressor gene p53 is implicated in the response of cancer cells to many cytotoxic agents (49, 50) . It was reported that several ruthenium-derived complexes led to G1 arrest and induced apoptosis in tumor cell lines derived from glioblastomas, neuroblastomas and lymphoid tumors at least as efficiently as cisplatin because both rutheniumderived complexes and cisplatin-induced p53-dependent and p53-independent apoptosis (1, 22) . Two p53 target genes, p21/WAF1 (Cdkn1a) and PUMA (Bbc3), linked to cell growth arrest and apoptosis, were selected to test if 2 and 3 can induce p53-dependent apoptosis. We observed that p21/WAF1 was approximately four-fold up-regulated in 2 and two-fold up-regulated in 3 while there were no obvious differences for PUMA gene expression in these two com- Table II. The selected bond lengths (Å) and bond angles (º) for the ruthenium complex 2. (Fig. 6a) . The ratio of pro-to anti-apoptotic genes has been reported to determine the threshold for the induction of mitochondrial-dependent apoptosis. Two anti-apoptotic genes Bcl-XL (Bcl2l1) and Bcl-2 showed two-to three-fold down-regulation by 2 and 3 (Fig. 6b) . It is interesting that another anti-apoptotic gene A1 (A1a, Bfl-1, Bcl2a1a) was three-to six-fold up-regulated in the treated cells by complexes 2 and 3 (Fig. 6c) . Ru complexes have been reported to exhibit potential for apoptosis induction and caused cell cycle arrest in the S phase as well as a decrease of the G1 and G2 percent of cancer cells (51) (52) (53) (54) (55) (56) . Two cell cycle-related genes cyclin D2 (Ccnd2) and cyclin E1 (Ccne1) showed approximately two-to three-fold down-regulation in complexes 2 and 3. cMyc plays an essential role in regulating cell cycle (57, 58) . We did not observe an obvious difference for cMyc gene expression in the cells treated with 2 and 3 (Fig. 6d) . The gene expression in 148 μM complex 1 is nearly the same as the control for all the tested genes.
Cell death by DNA fragmentation assay. Cell death may occur by two mechanisms: apoptosis and necrosis. During apoptosis, cellular endonucleases cleave nuclear DNA between nucleosomes, producing a mix of DNA fragments whose length varies in multiples of 180-200 bp. A ladder pattern in agarose gel is the key feature of apoptotic cells. On the other hand, the genomic DNA from necrotic cells has a random and general cleavage pattern. A genomic DNA smear is the key feature of necrotic cells. The RT-qPCR data suggest that the cells treated with 174 μM complex 2 and 226 μM complex 3 underwent the altered transcription programs. In order to distinguish the mechanisms of cell death caused by 2 and 3, we performed genomic DNA fragment assay. Partial DNA smear, rather than DNA ladder, was observed in the NIH3T3 cells treated by complexes 2 and 3 for 24 h, suggesting that cell death caused by 2 and 3 may undergo the necrotic pathway (Fig. 7) . No obvious DNA smear was observed in these complexes. 
Discussion
NAMI-A, the first ruthenium complex accomplished phase I clinical trials, belongs to the class of ruthenium dimethylsulfoxide complexes and shows a remarkable high efficiency against certain types of human tumors (1, 27, 28, 59) . Because of the S-bonded DMSO ligand, NAMI-A is easily reduced to the corresponding ruthenium(II) species by biological reducing agents under physiological conditions (60) . It has been proven that these reduced species maintain their anticancer activities. Ruthenium complexes 1 and 3 have DMSO ligands. Only complex 3 shows modest anticancer activity in our assays. It is possible that complex 3 is relatively easy to reduce compared to complex 1 although it needs further to be experimentally investigated. Both complexes 2 and 3 have similar anticancer activity. However, complex 3 has DNA binding activity while complex 2 does not. It has been reported that anticancer activity of ruthenium complexes appears not to be always related to their DNA binding activity (61) . Instead, some ruthenium complexes can interact with proteins. For example, NAMI-A interferes with fibrous collagen of the lung and with basement membrane collagen type IV. It significantly increases the thickness of connective tissue around the tumor capsule and around tumor blood vessels, thereby probably hindering blood flow to the tumor (1, 21) .
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